<SEC-DOCUMENT>0001193125-19-094698.txt : 20190401
<SEC-HEADER>0001193125-19-094698.hdr.sgml : 20190401
<ACCEPTANCE-DATETIME>20190401170602
ACCESSION NUMBER:		0001193125-19-094698
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190328
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190401
DATE AS OF CHANGE:		20190401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		19721636

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d678014d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): March&nbsp;28, 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Corporation plc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>England and Wales</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">0-21392</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2 Pembroke House, Upper Pembroke Street <FONT STYLE="white-space:nowrap">28-32,</FONT> Dublin
2,</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ireland</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: +353 1 6699 020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Former
name or former address, if changed since last report </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act
(17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or
Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 (17 CFR <FONT STYLE="white-space:nowrap">&#167;240.12b-2).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Events. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;28, 2019, Amarin Corporation plc issued a press release titled, &#147;Amarin Submits Supplemental New Drug Application (sNDA) to
U.S. FDA Seeking New Indication for Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) to Reduce the Risk of Major Adverse Cardiovascular Events Based on Landmark
<FONT STYLE="white-space:nowrap">REDUCE-IT&#153;</FONT> Cardiovascular Outcomes Study&#148; (the &#147;Press Release&#148;). A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Exhibit<br>No.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d678014dex991.htm">Press Release, dated March&nbsp;28, 2019 </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: April&nbsp;1, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Amarin Corporation plc</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Thero</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">John Thero</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d678014dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g678014g0401112429488.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Vascepa&reg; (icosapent ethyl) to Reduce the Risk of Major Adverse Cardiovascular Events Based on Landmark
<FONT STYLE="white-space:nowrap">REDUCE-IT</FONT><SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> Cardiovascular Outcomes Study </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BEDMINSTER, N.J., and DUBLIN, Ireland, March&nbsp;28, 2019 &#151; Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving
cardiovascular health, today announced that, as planned, it submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking an expanded indication for its lead product, Vascepa<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) capsules, based on the landmark <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT><SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> cardiovascular outcomes study<SUP
STYLE="font-size:85%; vertical-align:top">1, 2</SUP>. As is typical, while the FDA acknowledged receipt of the sNDA submission, at this stage FDA has not yet communicated to Amarin the intended timing of its review. Unless and until the company
learns otherwise in communications from the FDA, the review timing is typically communicated within 60 to 74 days of the FDA&#146;s receipt of an sNDA. Amarin is operating under the assumption that the sNDA will be reviewed on a standard review
clock of ten months resulting in a PDUFA date near the end of January 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This submission is another step forward toward our goal to help address
the risk of cardiovascular disease,&#148; said John F. Thero, president and chief executive officer of Amarin. &#147;The <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results support that approximately 1 fewer major cardiovascular adverse event
would occur on average for every 6 patients treated with Vascepa for 5 years on top of statin therapy compared to placebo<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>. This unprecedented result beyond cholesterol management presents an
important new preventative care opportunity for millions of patients.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is typical for a trial of this size, the electronic sNDA submission
consists of over 5&nbsp;million pages of information regarding Vascepa, including data from over 35,000 patient years of study in <FONT STYLE="white-space:nowrap">REDUCE-IT.</FONT> A total events analysis from the
<FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study was recently published online in the <I>Journal of the American College of Cardiology</I><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>, and the primary results of the <FONT
STYLE="white-space:nowrap">REDUCE-IT</FONT> study were previously published in <I>The</I> <I>New England Journal of Medicine</I><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>. In <FONT STYLE="white-space:nowrap">REDUCE-IT,</FONT> Vascepa
provided a 25% relative risk reduction compared to placebo in the first occurrence of a major adverse CV event (MACE) in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">intent-to-treat</FONT></FONT> population consisting of a
composite of cardiovascular death, nonfatal myocardial infarction (MI or heart attack), nonfatal stroke, coronary revascularization (procedures such as stents and <FONT STYLE="white-space:nowrap">by-pass)</FONT> and unstable angina requiring
hospitalization. For total (first and subsequent) cardiovascular events, Vascepa provided a statistically significant 30% risk reduction compared to placebo in the statin-treated patient population studied in
<FONT STYLE="white-space:nowrap">REDUCE-IT.</FONT> <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> was performed under a Special Protocol Assessment (SPA) with the FDA. In <FONT STYLE="white-space:nowrap">REDUCE-IT,</FONT> adverse events occurring
with Vascepa use at greater than 5% and greater than placebo were: peripheral edema (6.5% Vascepa versus 5.0%), although there was no increase in the rate of heart failure in Vascepa patients; constipation (5.3% Vascepa versus 3.6%), although
mineral oil, as used as placebo, is known to lower constipation; and atrial fibrillation (5.3% Vascepa versus 3.9%), although there were reductions in rates of cardiac arrest, sudden death and myocardial infarctions observed in Vascepa patients.
More information on safety data associated with <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> is provided below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin has previously expressed that it believes it is likely that there will be an Advisory Committee
(AdCom) meeting organized by the FDA in conjunction with its review of the expanded label for Vascepa sought in its sNDA based on the landmark results of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> cardiovascular outcomes study and the
very large patient population that Vascepa could potentially address. However, the FDA determination as to whether or not there will be an AdCom has not yet been communicated to Amarin. Typically, the FDA does not communicate such a decision until
it has had the opportunity to substantially review the sNDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Amarin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health.
Amarin&#146;s product development program leverages its extensive experience in polyunsaturated fatty acids and lipid science. Vascepa (icosapent ethyl) is Amarin&#146;s first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug and is
available by prescription in the United States, Lebanon and the United Arab Emirates. Amarin&#146;s commercial partners are pursuing additional regulatory approvals for Vascepa in Canada, China and the Middle East. For more information about Amarin,
visit www.amarincorp.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">REDUCE-IT</FONT><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>, an
<FONT STYLE="white-space:nowrap">8,179-patient</FONT> cardiovascular outcomes study, was completed in 2018. <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> was the first multinational cardiovascular outcomes study that evaluated the effect of
prescription pure EPA therapy as an <FONT STYLE="white-space:nowrap">add-on</FONT> to statins in patients with high cardiovascular risk who, despite stable statin therapy, had elevated triglyceride levels (at least 135 mg/dL). A large portion of the
male and female patients enrolled in this outcomes study were diagnosed with type 2 diabetes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More information on the
<FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study results can be found at www.amarincorp.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cardiovascular Disease </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Worldwide, cardiovascular disease (CVD) remains the #1 killer of men and women. In the United States CVD leads to one in every three deaths &#150; one death
approximately every 38 seconds &#150; with annual treatment cost in excess of $500&nbsp;billion.<SUP STYLE="font-size:85%; vertical-align:top">3, 4 </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Multiple&nbsp;primary and secondary prevention&nbsp;trials have shown a significant reduction of 25% to 35% in the risk of&nbsp;cardiovascular
events&nbsp;with&nbsp;statin&nbsp;therapy, leaving significant persistent residual risk despite the achievement of target <FONT STYLE="white-space:nowrap">LDL-C</FONT> levels.<SUP STYLE="font-size:85%; vertical-align:top">5</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beyond the cardiovascular risk associated with <FONT STYLE="white-space:nowrap">LDL-C,</FONT> genetic, epidemiologic, clinical and real-world data suggest
that patients with elevated triglycerides (TG) (fats in the blood), and <FONT STYLE="white-space:nowrap">TG-rich</FONT> lipoproteins, are at increased risk for cardiovascular disease.<SUP STYLE="font-size:85%; vertical-align:top"> 6, 7, 8, 9</SUP>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Vascepa&nbsp;(icosapent ethyl) Capsules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa (icosapent ethyl) capsules are a single-molecule prescription product consisting of the <FONT STYLE="white-space:nowrap">omega-3</FONT> acid commonly
known as EPA in ethyl-ester form. Vascepa is not fish oil, but is derived from fish through a stringent and complex <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> manufacturing process designed to effectively eliminate impurities and isolate
and protect the single molecule active ingredient from degradation. Vascepa, known in scientific literature as AMR101, has been designated a new chemical entity by the FDA. Amarin has been issued multiple patents internationally based on the unique
clinical profile of Vascepa, including the drug&#146;s ability to lower triglyceride levels in relevant patient populations without raising <FONT STYLE="white-space:nowrap">LDL-cholesterol</FONT> levels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Indication and Usage Based on Current <FONT STYLE="white-space:nowrap">FDA-Approved</FONT> Label (not including
<FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results) </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients
with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The effect of Vascepa on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with
severe hypertriglyceridemia has not been determined. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Important Safety Information for Vascepa Based on Current <FONT
STYLE="white-space:nowrap">FDA-Approved</FONT> Label (not including <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results) (Includes Data from Two <FONT STYLE="white-space:nowrap">12-Week</FONT> Studies (n=622) (MARINE and ANCHOR) of Patients
with Triglycerides Values of 200 to 2000 mg/dL) </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Vascepa is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to Vascepa or
any of its components. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Use with caution in patients with known hypersensitivity to fish and/or shellfish. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The most common reported adverse reaction (incidence &gt;2% and greater than placebo) was arthralgia (2.3% for
Vascepa, 1.0% for placebo). There was no reported adverse reaction &gt;3% and greater than placebo. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adverse events and product complaints may be reported by calling <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-855-VASCEPA</FONT></FONT> or the FDA at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-FDA-1088.</FONT></FONT></FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients receiving treatment with Vascepa and other drugs affecting coagulation (e.g., anti-platelet agents)
should be monitored periodically. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients should be advised to swallow Vascepa capsules whole; not to break open, crush, dissolve, or chew
Vascepa. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Important Safety Information for Vascepa based on <FONT STYLE="white-space:nowrap">REDUCE-IT,</FONT> as previously reported in </U><I><U>The
New England Journal of Medicine</U></I><U><SUP STYLE="font-size:85%; vertical-align:top">2</SUP></U> <U>publication of the primary results of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study: </U> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Excluding the major adverse cardiovascular events (MACE) results described above, overall adverse event rates in <FONT
STYLE="white-space:nowrap">REDUCE-IT</FONT> were similar across the statin plus Vascepa and the statin plus placebo treatment groups. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There were no significant differences between treatments in the overall rate of treatment emergent adverse events
or serious adverse events leading to withdrawal of study drug. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There was no serious adverse event (SAE) occurring at a frequency of &gt;2% which occurred at a numerically
higher rate in the statin plus Vascepa treatment group than in the statin plus placebo treatment group. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adverse events (AEs) occurring in 5% or greater of patients and more frequently with Vascepa than placebo were:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">peripheral edema (6.5% Vascepa patients versus 5.0% placebo patients), although there was no increase in the rate
of heart failure in Vascepa patients </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">constipation (5.4% Vascepa patients versus 3.6% placebo patients), although mineral oil, as used as placebo, is
known to lower constipation, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">atrial fibrillation (5.3% Vascepa patients versus 3.9% placebo patients), although there were reductions in rates
of cardiac arrest, sudden death and myocardial infarctions observed in Vascepa patients </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There were numerically more SAEs related to bleeding in the statin plus Vascepa treatment group although overall
rates were low with no fatal bleeding observed in either group and no significant difference in adjudicated hemorrhagic stroke or serious central nervous system or gastrointestinal bleeding events between treatments. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In summary, Vascepa was well tolerated with a safety profile generally consistent with clinical experience
associated with <FONT STYLE="white-space:nowrap">omega-3</FONT> fatty acids and current <FONT STYLE="white-space:nowrap">FDA-approved</FONT> labeling of such products. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vascepa has been approved for use by the United States Food and Drug Administration (FDA) as an adjunct to diet to reduce triglyceride levels in adult
patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia. FDA has not reviewed and opined on a supplemental new drug application related to <FONT STYLE="white-space:nowrap">REDUCE-IT.</FONT> FDA has not
reviewed the information herein or determined whether to approve Vascepa for use to reduce the risk of MACE. Nothing in this press release should be construed as promoting the use of Vascepa in any indication that has not been approved by the FDA.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Cautionary Information About These Data </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> data assessment and data release could yield additional useful information to inform greater
understanding of the trial outcome. Further detailed data assessment by&nbsp;Amarin&nbsp;and regulatory authorities will continue and take several months to complete and record. The final evaluation of the totality of the efficacy and safety data
from <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> may include some or all of the following, as well as other considerations: new information affecting the degree of treatment benefit on studied endpoints; study conduct and data robustness,
quality, integrity and consistency; additional safety data considerations and risk/benefit considerations; consideration of <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results in the context of other clinical studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recurrent event analyses for the total primary endpoint events and for the total key secondary endpoint in <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT>
as published in the <I>Journal of the American College of Cardiology</I><SUP STYLE="font-size:85%; vertical-align:top">1</SUP><I> </I>were conducted using a series of statistical models. These analyses were tertiary or exploratory endpoints; most of
the models used were prespecified and one was post hoc. Each recurrent event statistical model has inherent strengths and weaknesses, with no single model considered definitive or outperforming the other models, and this is an evolving field of
science. Nonetheless, results from the total primary and total key </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
secondary endpoint events analyses are consistent across the various recurrent event statistical models and are also consistent with the original primary and secondary endpoint results. Together,
the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> recurrent event analyses and the original primary and key secondary endpoint analyses support the robustness of the clinical benefit of Vascepa therapy in reducing cardiovascular risk. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements, including expectations regarding FDA review and related timelines, that <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results could lead to a new treatment paradigm in the patient population studied and present an
important new preventative care opportunity for millions of patients. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. In addition, Amarin&#146;s ability to effectively commercialize
Vascepa will depend in part on its ability to continue to effectively finance its business, efforts of third parties, its ability to gain regulatory approvals, create market demand for Vascepa through education, marketing and sales activities, to
achieve market acceptance of Vascepa, to receive adequate levels of reimbursement from third-party payers, to develop and maintain a consistent source of commercial supply at a competitive price, to comply with legal and regulatory requirements in
connection with the sale and promotion of Vascepa and to maintain patent protection for Vascepa. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties
associated generally with research and development, clinical trials and related regulatory approvals; the risk that sales may not meet expectations and related cost may increase beyond expectations; the risk that patents may not be upheld in patent
litigation and applications may not result in issued patents sufficient to protect the Vascepa franchise. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in
Amarin&#146;s filings with the U.S. Securities and Exchange Commission, including its most recent annual report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> Existing and prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or
otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Availability of Other Information About Amarin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor
relations website (investor.amarincorp.com), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts
on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor
relations website, on a regular basis. This list of channels may be updated from time to time on Amarin&#146;s investor relations website and may include social media channels. The contents of Amarin&#146;s website or these channels, or any other
website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>References </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bhatt DL, Steg PG, Miller M, et al. Effects of Icosapent Ethyl on Total Ischemic Events: From <FONT
STYLE="white-space:nowrap">REDUCE-IT.</FONT> <I>J Am Coll Cardiol</I> 2019. epub ahead of print. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">http://www.onlinejacc.org/content/early/2019/03/01/j.jacc.2019.02.032 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for
Hypertriglyceridemia. <I>N Engl J Med</I> <FONT STYLE="white-space:nowrap">2019;380:11-22.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">American Heart Association. 2018. Disease and Stroke Statistics-2018 Update. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">American Heart Association. 2017. Cardiovascular disease: A costly burden for America projections through 2035.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">5</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia
management. <I>J Am Coll Cardiol</I>. <FONT STYLE="white-space:nowrap">2018;72(3):330-343.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">6</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease.
<I>Am J Cardiol</I>. <FONT STYLE="white-space:nowrap">2016;118:138-145.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">7</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Toth PP, Granowitz C, Hull M, et al. High triglycerides are associated with increased cardiovascular events,
medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. <I>J Am Heart Assoc.</I> 2018;7(15):e008740. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">8</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease - New insights from
epidemiology, genetics, and biology. <I>Circ Res</I>. <FONT STYLE="white-space:nowrap">2016;118:547-563.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">9</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. <I>Lancet.</I> 2014;384:626&#150;635.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amarin Contact Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investor Relations: </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elisabeth Schwartz </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin
Corporation plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;U.S.: +1 (908) <FONT STYLE="white-space:nowrap">719-1315</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">investor.relations@amarincorp.com (investor inquiries) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PR@amarincorp.com (media inquiries) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lee M. Stern </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Solebury Trout </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;U.S.: +1 (646) <FONT
STYLE="white-space:nowrap">378-2992</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>lstern@soleburytrout.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g678014g0401112429488.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g678014g0401112429488.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] 2\# 2(  A$! Q$!_\0
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MPZ$$9!J6N,Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.X/]*5-+DO3W'-OFM(^E_"7A>T\):%%IMJQD(.Z65A@R.>IJ'Q[_ ,B)K/\
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86RQR>@%;SJ\\+/<SC#EE=&S1116!H?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
